Información del artículo
Resumen
Introducción
El presente artículo busca presentar las recomendaciones basadas en la evidencia que surgieron como respuesta a una serie de preguntas clínicas respecto al episodio depresivo y al trastorno depresivo recurrente, haciendo hincapié en los aspectos generales de tratamiento, el tratamiento en la fase aguda y el manejo de la fase de continuación/mantenimiento, con el fin de brindar parámetros de atención en salud basados en la mejor y más actualizada evidencia disponible para lograr los estándares mínimos de calidad en el abordaje de adultos con dichos diagnósticos.
MétodoSe elaboró una guía de práctica clínica bajo los lineamientos de la Guía Metodológica del Ministerio de la Protección Social. Se adaptaron las recomendaciones de las guías NICE90 y CANMAT para las preguntas que estas guías contestaban y se desarrollaron de novo para las preguntas no encontradas.
ResultadosSe presentan las recomendaciones 5-22 correspondientes al manejo de la depresión.
Palabras clave:
Guía de práctica clínica
trastorno depresivo
farmacoterapia
psicoterapia
antidepresivos
Abstract
Introduction
This article presents recommendations based on evidence gathered to answer a series of clinical questions concerning the depressive episode and the recurrent depressive disorder, with emphasis on general treatment aspects, treatment in the acute phase and management of the continuation/maintenance, all intended to grant health care parameters based on the best and more updated available evidence for achieving minimum quality standards with adult patients thus diagnosed.
MethodologyA practical clinical guide was elaborated according to standards of the Methodological Guide of the Ministry of Social Protection. Recommendation from NICE90 and CANMAT guides were adopted and updated so as to answer the questions posed while de novo questions were developed.
ResultsRecommendations 5-22 corresponding to management of depression are presented.
Key words:
Practice guideline
depressive disorder
drug therapy
psychotherapy
antidepressive agents
El Texto completo está disponible en PDF
Referencias citadas
[1]
DP, GS Perry, TW Strine.
The vital link between chronic disease and depressive disorders.
Prev Chronic Dis, 2 (2005), pp. A14
[2]
RZ Goetzel, K Hawkins, RJ Ozminkowski, et al.
The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999.
J Occup Environ Med, 45 (2003), pp. 5-14
[4]
M Zimmerman, M Posternak, M Friedman, et al.
Which factors influence psychiatrists' selection of antidepressants?.
Am J Psychiatry, 161 (2004), pp. 1285-1289
[5]
SH Kennedy, SJ Rizvi.
Emerging drugs for major depressive disorder.
Expert Opin Emerg Drugs, 14 (2009), pp. 439-453
[6]
M Fava, AJ Rush, MH Trivedi, et al.
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.
Psychiatr Clin North Am, 26 (2003), pp. 457-494
[7]
K Zivin, D Ganoczy, PN Pfeiffer, et al.
Antidepressant adherence after psychiatric hospitalization among VA patients with depression.
Adm Policy Ment Health, 36 (2009), pp. 406-415
[8]
J Wang, X Liu, CD Mullins.
Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Curr Med Res Opin, 27 (2011), pp. 1303-1313
[9]
HC Lin, S Erickson, R Blakrishnan.
Antidepressant utilization, adherence, and health care spending in the United States: the case of MDD patients 2000-2007.
Health Outcomes Res Med, 2 (2011), pp. e79-e89
[10]
IA Holma, KM Holma, TK Melartin, et al.
Treatment attitudes and adherence of psychiatric patients with major depressive disorder: a five-year prospective study.
J Affect Disord, 127 (2010), pp. 102-112
[11]
CL Bockting, MC ten Doesschate, J Spijker, et al.
Continuation and maintenance use of antidepressants in recurrent depression.
Psychother Psychosom, 77 (2008), pp. 17-26
[12]
RB Haynes, E Ackloo, N Sahota, et al.
Interventions for enhancing medication adherence.
Cochrane Database Syst Rev, (2008),
[13]
M Olfson, SC Marcus, M Tedeschi, et al.
Continuity of antidepressant treatment for adults with depression in the United States.
Am J Psychiatry, 163 (2006), pp. 101-108
[14]
MC Serna, I Cruz, J Real, et al.
Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database.
Eur Psychiatry, 25 (2010), pp. 206-213
[15]
D Hodgkin, J Volpe-Vartanian, M Alegría.
Discontinuation of antidepressant medication among Latinos in the USA.
J Behav Health Serv Res, 34 (2007), pp. 329-342
[16]
SB Woolley, L Fredman, JW Goethe, et al.
Hospital patients' perceptions during treatment and early discontinuation of serotonin selective reuptake inhibitor antidepressants.
J Clin Psychopharmacol, 30 (2010), pp. 716-719
[17]
A Boyle.
A novel approach to the psychopharmacologic treatment of insomnia in depression.
Med Hypotheses, 63 (2004), pp. 26-30
[18]
SV Parikh, ZV Segal, S Grigoriadis, et al.
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication.
J Affect Disord, 117 (2009), pp. S15-S25
[19]
J Krogh, M Nordentoft, JA Sterne, et al.
The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials.
J Clin Psychiatry, 72 (2011), pp. 529-538
[20]
J Mota-Pereira, J Silverio, S Carvalho, et al.
Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder.
J Psychiatr Res, 45 (2011), pp. 1005-1011
[21]
R Ramana, ES Paykel, Z Cooper, et al.
Remission and relapse in major depression: a two-year prospective follow-up study.
Psychol Med, 25 (1995), pp. 1161-1170
[22]
RT Mulder, CM Frampton, SE Luty, et al.
Eighteen months of drug treatment for depression: predicting relapse and recovery.
J Affect Disord, 114 (2009), pp. 263-270
[23]
JB Williams.
Standardizing the Hamilton depression rating scale: past, present, and future.
Eur Arch Psychiatry Clin Neurosci, 251 (2001), pp. II6-I12
[24]
LV Kessing, MG Hansen, PK Andersen, et al.
The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders – a life-long perspective.
Acta Psychiatr Scand, 109 (2004), pp. 339-344
[25]
NIMH/NIH Consensus Development Conference statement.
Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel.
Am J Psychiatry, 142 (1985), pp. 469-476
[Adler et al., 2011]
UC Adler, S Krüger, M Teut, et al.
Homeopathy for depression-DEP-HOM: study protocol for a randomized, partially double-blind, placebo controlled, four armed study.
Trials, 12 (2011), pp. 43
[Adli et al., 2005]
M Adli, C Baethge, A Heinz, et al.
Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed?.
Eur Arch Psychiatry Clin Neurosci, 255 (2005), pp. 387-400
[Alarcón, 2004]
R Alarcón.
A propósito de la pseudodemencia y la depresión de inicio tardío en los estados demenciales.
Rev Col Psiquiatría, 33 (2004), pp. 387-398
[Allen et al., 2006]
JJ Allen, RN Schnyer, AS Chambers, et al.
Acupuncture for depression: a randomized controlled trial.
J Clin Psychiatry, 67 (2006), pp. 1665-1673
[Andreasen and Black, 2001]
N Andreasen, D Black.
Introductory textbook of psychiatry, 3rd ed., American Psychiatric Publishing, (2001),
[Andreescu et al., 2007]
C Andreescu, EJ Lenze, MA Dew, et al.
Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study.
Br J Psychiatry, 190 (2007), pp. 344-349
[Antunes et al., 2005]
HK Antunes, SG Stella, RF Santos, et al.
Depression, anxiety and quality of life scores in seniors after an endurance exercise program.
Rev Bras Psiquiatr, 27 (2005), pp. 266-271
[Babyak et al., 2000]
M Babyak, JA Blumenthal, S Herman, et al.
Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months.
Psychosom Med, 62 (2000), pp. 633-638
[Bagby et al., 2004]
RM Bagby, AG Ryder, DR Schuller, et al.
The Hamilton Depression Rating Scale: has the gold standard become a lead weight?.
Am J Psychiatry, 161 (2004), pp. 2163-2177
[Bair et al., 2004]
MJ Bair, RL Robinson, GJ Eckert, et al.
Impact of pain on depression treatment response in primary care.
Psychosom Med, 66 (2004), pp. 17-22
[Baldwin et al., 2009]
DS Baldwin, DJ Stein, OT Dolberg, et al.
How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalized anxiety disorder or social anxiety disorder? An exploration of the randomized controlled trial database.
Hum Psychopharmacol, 24 (2009), pp. 269-275
[Ballesteros et al., 2007]
J Ballesteros, J Bobes, A Bulbena, et al.
Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD).
J Affect Disord, 102 (2007), pp. 93-99
[Barbui et al., 2009]
C Barbui, E Espósito, A Cipriani.
Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies.
CMAJ, 180 (2009), pp. 291-297
[Barker et al., 2012]
ED Barker, W Copeland, B Maughan, et al.
Relative impact of maternal depression and associated risk factors on offspring psychopathology.
Br J Psychiatry, 200 (2012), pp. 124-129
[Bauer et al., 2008]
M Bauer, BU Monz, AI Montejo, et al.
Prescribing patterns of antidepressants in Europe: Results fron the Factors Influencing Depression Endpoints Research (FINDER) study.
Eur Psychiatry, 23 (2008), pp. 66-73
[Berlin and Lavergne, 1998]
I Berlin, F Lavergne.
Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction.
Eur. Psychiatry, 13 (1998), pp. 138-142
[Bermejo et al., 2010]
I Bermejo, L Kriston, F Schneider, et al.
Sick leave and depression – determining factors and clinical effect in outpatient care.
Psychiatry Res, 180 (2010), pp. 68-73
[Bilsker et al., 2006]
D Bilsker, S Wiseman, M Gilbert.
Managing depression-related occupational disability: a pragmatic approach.
Can J Psychiatry, 51 (2006), pp. 76-83
[Bockting et al., 2009]
CL Bockting, P Spinhoven, LF Wouters, et al.
Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study.
J Clin Psychiatry, 70 (2009), pp. 1621-1628
[Bockting et al., 2008]
CLH Bockting, MC Doesschate, J Spikjer, et al.
Continuation and manteinance use of antidepressants in recurrent depression.
Psychother Psychosonm, 77 (2008), pp. 17-26
[Bollini et al., 1999]
P Bollini, S Pampallona, G Tibaldi, et al.
Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials.
Br J Psychiatry, 174 (1999), pp. 297-303
[Bosuño et al., 2001]
M Bosuño, PA Saiz, M González Quirós, et al.
Tratamiento de los trastornos de ansiedad y depresión en situaciones especiales.
Trastornos de ansiedad y trastornos depresivos en atención primaria, pp. 197-216
[Boyle, 2004]
A Boyle.
A novel approach to the psychopharmacologic treatment of insomnia in depression.
Med Hypotheses, 63 (2004), pp. 26-30
[Brundtland, 2000]
GH Brundtland.
La salud mental en siglo XXI.
Bull World Health Org, 78 (2000), pp. 411
[Carmody et al., 2006]
TJ Carmody, AJ Rush, I Bernstein, et al.
The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures.
Eur Neuropsychopharmacol, 16 (2006), pp. 601-611
[Carter et al., 2011]
JD Carter, SE Luty, JM McKenzie, et al.
Patient predictors of response to cognitive behaviour therapy and interpersonal psychotherapy in a randomised clinical trial for depression.
J Affect Disord, 128 (2011), pp. 252-261
[Charbonneau et al., 2003]
A Charbonneau, AK Rosen, AS Ash, et al.
Measuring the quality of depression care in a large integrated health system.
Med Care, 41 (2003), pp. 669-680
[Chen et al., 2008]
Y Chen, JJ Guo, H Li, et al.
Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study.
Ann Pharmacother, 42 (2008), pp. 177-184
[Cheuk et al., 2007]
DKL Cheuk, J Yeung, K Chung, et al.
Acupuncture for insomnia.
Cochrane Database Syst Rev, (2007),
[Chiesa and Serretti, 2010]
A Chiesa, A Serretti.
Mindfulness based cognitive therapy for major depression: A systematic review and meta-analysis.
European Psychiatry, 25 (2010), pp. 1045
[Cipriani et al., 2009]
A Cipriani, TA Furukawa, G Salanti, et al.
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Lancet, 373 (2009), pp. 746-758
[Cipriani et al., 2009]
A Cipriani, T La Ferla, TA Furukawa, et al.
Sertraline versus other antidepressive agents for depression.
Cochrane Database Syst Rev, (2009),
[Coechiarella and Andersson, 2001]
L Coechiarella, G Andersson.
Guides to the evaluation of permanent impairment, 5th ed., American Medical Association Press, (2001),
[Conradi et al., 2007]
HJ Conradi, P de Jonge, H Kluiter, et al.
Enhanced treatment for depression in primary care: long-term outcomes of a psycho-educational prevention program alone and enriched with psychiatric consultation or cognitive behavioral therapy.
Psychol Med, 37 (2007), pp. 849-862
[Costello et al., 1991]
AJ Costello, MK Dulcan, R Kalas.
A checklist of hospitalization criteria for use with children.
Hosp Com Psychiatry, 42 (1991), pp. 823-828
[Coupland et al., 2011]
CAC Coupland, P Dhiman, G Barton, et al.
A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database.
Health Technol Assess, 15 (2011), pp. 1-202
[Cuijpers et al., 2011]
P Cuijpers, G Andersson, T Donker, et al.
Psychological treatment of depression: results of a series of meta-analyses.
Nord J Psychiatry, 65 (2011), pp. 354-364
[Cuijpers et al., 2008]
P Cuijpers, A van Straten, G Andersson, et al.
Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies.
J Consult Clin Psychol, 76 (2008), pp. 909-922
[Cuijpers et al., 2008]
P Cuijpers, A van Straten, P van Oppen, et al.
Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies.
J Clin Psychiatry, 69 (2008), pp. 1675-1685
[Cuijpers et al., 2009]
P Cuijpers, A van Straten, A van Schaik, et al.
Psychological treatment of depression in primary care: a meta-analysis.
Br J Gen Pract, 59 (2009), pp. e51-e60
[Cuijpers et al., 2009]
P Cuijpers, A van Straten, L Warmerdam, et al.
Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis.
Depress Anxiety, 26 (2009), pp. 279-288
[Cuijpers et al., 2008]
P Cuijpers, A van Straten, L Warmerdam.
Are individual and group treatments equally effective in the treatment of depression in adults? A meta-analysis.
Eur J Psychiat, 22 (2008), pp. 38-51
[Cusin et al., 2010]
C Cusin, H Yang, A Yeung, et al.
Rating scales for depression.
Handbook of clinical rating scales and assessment in psychiatry and mental health, pp. 7-36
[Daley, 2008]
A Daley.
Exercise and depression: a review of reviews.
J Clin Psychol Med Settings, 15 (2008), pp. 140-147
[Daly et al., 2011]
EJ Daly, MH Trivedi, M Fava, et al.
The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study.
J Clin Psychopharmacol, 31 (2011), pp. 31-38
[Demyttenaere et al., 2008]
K Demyttenaere, A Bonnewyn, R Bruffaerts, et al.
Clinical factors influencing the prescription of antidepressants and benzodiazepines: Results from the European study of the epidemiology of mental disorders (ESEMeD).
J Affect Disord, 110 (2008), pp. 84-93
[DeRubeis et al., 2005]
RJ DeRubeis, SD Hollon, JD Amsterdam, et al.
Cognitive therapy Vs. medications in the treatment of moderate to severe depression.
Arch Gen Psychiatry, 62 (2005), pp. 409-416
[Di Nasso et al., 2011]
E Di Nasso, A Chiesa, A Serretti, et al.
Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study.
Clin Drug Investig, 31 (2011), pp. 385-405
[Dickinson et al., 2010]
R Dickinson, P Knapp, AO House, et al.
Long-term prescribing of antidepressants in the older population: a qualitative study.
Br J Gen Pract, 60 (2010), pp. 144-155
[Dombrovski et al., 2008]
AY Dombrovski, JM Cyranowski, BH Mulsant, et al.
Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?.
Depress Anxiety, 25 (2008), pp. 1060-1066
[Donker et al., 2009]
T Donker, KM Griffiths, P Cuijpers, et al.
Psychoeducation for depression, anxiety and psychological distress: a meta-analysis.
BMC Med, 7 (2009), pp. 79
[Dotoli et al., 2006]
D Dotoli, ZC Spagnolo, F Bongiorno, et al.
Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables.
Prog Neuropsychopharmacol Biol Psychiatry, 30 (2006), pp. 442-448
[Driessen et al., 2010]
E Driessen, P Cuijpers, SD Hollon, et al.
Does pretreatment severity moderate the efficacy of psychological treatment of adult outpatient depression? A meta-analysis.
J Consult Clin Psychol, 78 (2010), pp. 668-680
[Driessen et al., 2010]
E Driessen, P Cuijpers, S Maat, et al.
The efficacy of short term psychodynamic psychotherapy for depression: A meta-analysis.
Clin Psychol Rev, 30 (2010), pp. 25-36
[Duan et al., 2009]
DM Duan, Y Tu, LP Chen, et al.
Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine.
J Tradit Chin Med, 29 (2009), pp. 167-173
[Ekers et al., 2008]
D Ekers, D Richards, S Gilbody.
A meta-analysis of randomized trials of behavioural treatment of depression.
Psych Med, 38 (2008), pp. 611-623
[Erkkilä et al., 2011]
J Erkkilä, M Punkanen, J Fachner, et al.
Individual music therapy for depression: randomized controlled trial.
Br J Psychiatry, 199 (2011), pp. 132-139
[Eyding et al., 2010]
D Eyding, M Lelgemann, U Grouven, et al.
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.
BMJ, 341 (2010), pp. c4737
[Fava et al., 1998]
GA Fava, C Rafanelli, S Grandi, et al.
Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression.
Am J Psychiatry, 155 (1998), pp. 1443-1445
[Fava et al., 2011]
M Fava, GM Asnis, RK Shrivastava, et al.
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
J Clin Psychiatry, 72 (2011), pp. 914-928
[Fava et al., 2006]
M Fava, WV McCall, A Krystal, et al.
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Biol Psychiatry, 59 (2006), pp. 1052-1060
[Fava et al., 2003]
M Fava, AJ Rush, MH Trivedi, et al.
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.
Psychiatr Clin North Am, 26 (2003), pp. 457-494
[Fergusson et al., 2005]
D Fergusson, S Doucette, KC Glass, et al.
Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.
BMJ, 330 (2005), pp. 396
[Forsell, 2005]
Y Forsell.
The major depression inventory versus schedules for clinical assessment in neuropsychiatry in a population sample.
Soc Psychiatry Psychiatr Epidemiol, 40 (2005), pp. 209-213
[Fournier et al., 2009]
JC Fournier, RJ De Rubeis, RC Shelton, et al.
Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression.
J Consult Clin Psychol, 77 (2009), pp. 775-787
[Fournier et al., 2010]
JC Fournier, RJ DeRubeis, SD Hollon, et al.
Antidepressant drug effects and depression severity.
JAMA, 303 (2010), pp. 47-53
[Frank et al., 2011]
E Frank, GB Cassano, P Rucci, et al.
Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and ISRS pharmacotherapy.
Psychol Med, 41 (2011), pp. 151-162
[Fundación Unidos contra la depresión y otros trastornos (FUNIDEP), 2012]
Fundación Unidos contra la depresión y otros trastornos (FUNIDEP) [internet]. 2012 [citado: 20 de septiembre de 2012].
[Furukawa et al., 2002]
TA Furukawa, D Streiner, LT Young, et al.
Antidepressants plus benzodiacepines for mayor depression.
Cochrane Database Syst Rev, (2002),
[Gagne et al., 2011]
JJ Gagne, AR Patrick, H Mogun, et al.
Antidepressants and fracture risk in older adults: a comparative safety analysis.
Clin Pharmacol Ther, 89 (2011), pp. 880-887
[Gardarsdottir et al., 2009]
H Gardarsdottir, TC Egberts, JJ Stolker, et al.
Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias.
Am J Epidemiol, 170 (2009), pp. 280-285
[Gartlehner et al., 2011]
G Gartlehner, RA Hansen, LC Morgan, et al.
Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review.
Ag Healthcare Res Qual, (2011),
[Gartlehner et al., 2008]
G Gartlehner, P Thieda, RA Hansen, et al.
Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis.
Drug Saf, 31 (2008), pp. 851-865
[Gaster, 2000]
B Gaster.
St John's wort for depression. A systematic review.
Arch Int Med, 160 (2000), pp. 152-156
[Geddes et al., 2003]
JR Geddes, SM Carney, C Davies, et al.
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review.
Lancet, 361 (2003), pp. 653-661
[Gensichen et al., 2009]
J Gensichen, M von Korff, M Peitz, et al.
Case management for depression by health care assistants in small primary care practices a cluster randomized trial.
Ann Intern Med, 151 (2009), pp. 369-378
[Glue et al., 2010]
P Glue, MR Donovan, S Kolluri, et al.
Meta-analysis of relapse prevention antidepressant trial in depressive disorders.
Aust New Zeal J Psychiatry, 8 (2010), pp. 697-705
[Guaiana et al., 2007]
G Guaiana, C Barbui, M Hotopf.
Amitriptyline for depression.
Cochrane Database Syst Rev, (2007),
[Guidi et al., 2011]
J Guidi, G Fava, M Fava, et al.
Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary metaanalysis.
Psych Med, 41 (2011), pp. 321-331
[Guthrie et al., 1999]
E Guthrie, J Moorey, F Margison.
Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilisers of psychiatric services.
Arch Gen Psychiatry, 56 (1999), pp. 519-526
[Hale et al., 2010]
A Hale, RM Corral, C Mencacci, et al.
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Int Clin Psychopharmacol, 25 (2010), pp. 305-314
[Hansen et al., 2008]
R Hansen, B Gaynes, P Thieda, et al.
Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants.
Psychiatr Serv, 59 (2008), pp. 1121-1130
[Harlem, 2000]
B Harlem.
La salud mental en el siglo XXI.
Bull World Health Org, 78 (2000), pp. 411
[Hattori et al., 2010]
H Hattori, K Yoshiyama, R Miura, et al.
Clinical psychological tests useful for differentiating depressive state with Alzheimer's disease from major depression of the elderly.
Psychogeriatrics, 10 (2010), pp. 29-33
[Haynes et al., 2008]
RB Haynes, E Ackloo, N Sahota, et al.
Interventions for enhancing medication adherence.
Cochrane Database Syst Rev, (2008),
[Heirs and Dean, 2007]
M Heirs, ME Dean.
Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder.
Cochrane Database Syst Rev, (2007),
[Henkel et al., 2009]
V Henkel, F Seemüller, M Obermeier, et al.
Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
J Affect Disord, 115 (2009), pp. 439-449
[Herman et al., 2002]
S Herman, JA Blumenthal, M Babyak, et al.
Exercise therapy for depression in middle-aged and older adults: predictors of early dropout and treatment failure.
Health Psychol, 21 (2002), pp. 553-563
[Hodgkin et al., 2007]
D Hodgkin, J Volpe-Vartanian, M Alegríia.
Discontinuation of antidepressant medication among Latinos in the USA.
J Behav Health Serv Res, 34 (2007), pp. 329-342
[Hoffman et al., 2011]
BM Hoffman, MA Babyak, WE Craighead, et al.
Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study.
Psychosom Med, 73 (2011), pp. 127-133
[Hollon et al., 2005]
SD Hollon, RJ DeRubeis, RC Shelton, et al.
Prevention of relapse following cognitive therapy vs. medications in moderate to severe depression.
Arch Gen Psychiatry, 62 (2005), pp. 417-422
[Holma et al., 2010]
IAK Holma, KM Holma, TK Melartin, et al.
Treatment attitudes and adherence of psychiatric patients with major depressive disorder: A five-year prospective study.
J Affect Disord, 127 (2010), pp. 102-112
[Jarrett et al., 2008]
RB Jarrett, JR Vittengl, LA Clark.
How much cognitive therapy, for which patients, will prevent depressive relapse?.
J Affect Disord, 111 (2008), pp. 185-192
[Jick and Li, 2008]
S Jick, L Li.
Antidepressant drug use and risk of venous thromboembolism.
Pharmacotherapy, 28 (2008), pp. 144-150
[Jindal, 2009]
RD Jindal.
Insomnia in patients with depression: some pathophysiological and treatment considerations.
CNS Drugs, 23 (2009), pp. 309-329
[Johnstone et al., 2009]
JM Johnstone, SE Luty, JD Carter, et al.
Childhood neglect and abuse as predictors of antidepressant response in adult depression.
Depress Anxiety, 26 (2009), pp. 711-717
[Kasper et al., 2010]
S Kasper, G Hajak, K Wulff, et al.
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
J Clin Psychiatry, 71 (2010), pp. 109-120
[Kaymaz et al., 2008]
N Kaymaz, J van Os, AJ Loonen, et al.
Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials.
J Clin Psychiatry, 69 (2008), pp. 1423-1436
[Keers et al., 2010]
R Keers, R Uher, B Gupta, et al.
Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP.
J Affect Disord, 127 (2010), pp. 337-342
[Kendrick et al., 2009]
T Kendrick, C Dowrick, A McBride, et al.
Management of depression in UK general practice in relation to scores on depression severity questionnaires: analysis of medical record data.
BMJ, 338 (2009), pp. b750
[Kennedy and Emsley, 2006]
SH Kennedy, R Emsley.
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
Eur Neuropsychopharmacol, 16 (2006), pp. 93-100
[Kennedy et al., 2009]
SH Kennedy, RW Lam, SV Parikh, et al.
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults.
J Affect Disord, 117 (2009), pp. S1-64
[Kennedy and Rizvi, 2009]
SH Kennedy, SJ Rizvi.
Emerging drugs for major depressive disorder.
Expert Opin Emerg Drugs, 14 (2009), pp. 439-453
[Kennedy et al., 2008]
SH Kennedy, S Sakina, K Fulton, et al.
A Double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
J Clin Psychopharmacol, 28 (2008), pp. 329-333
[Kessing et al., 2004]
LV Kessing, MG Hansen, PK Andersen, et al.
The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders – a life-long perspective.
Acta Psychiatr Scand, 109 (2004), pp. 339-344
[Kim et al., 2010]
HM Kim, K Zivin, D Ganoczy, et al.
predictors of antidepressant initiation among U.S. veterans diagnosed with depression.
Pharmacoepidemiol Drug Saf, 19 (2010), pp. 1049-1056
[Kim et al., 2011]
SW Kim, R Stewart, JM Kim, et al.
Relationship between a history of a suicide attempt and treatment outcomes in patients with depression.
J Clin Psychopharmacol, 31 (2011), pp. 449-456
[Knubben et al., 2007]
K Knubben, FM Reischies, M Adli, et al.
A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depression.
Br J Sports Med, 41 (2007), pp. 29-33
[Kok et al., 2009]
RM Kok, M Aartsen, WA Nolen, et al.
The course of adverse effects of nortriptyline and venlafaxine in elderly patients with major depression.
J Am Geriatr Soc, 57 (2009), pp. 2112-2117
[Krogh et al., 2011]
J Krogh, M Nordentoft, JA Sterne, et al.
The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials.
J Clin Psychiatry, 72 (2011), pp. 529-538
[Kupfer, 1991]
DJ Kupfer.
Long-term treatment of depression.
J Clin Psychiatry, 52 (1991), pp. S28-S34
[Kuyken et al., 2008]
W Kuyken, S Byford, RS Taylor, et al.
Mindfulness-based cognitive therapy to prevent relapse in recurrent depression.
J Consult Clin Psychol, 76 (2008), pp. 966-978
[Kwan et al., 2010]
BM Kwan, S Dimidjian, S Rizvib.
Treatment preference, engagement, and clinical improvement in pharmacotherapy versus psychotherapy for depression.
Behav Res Ther, 48 (2010), pp. 799-804
[Lam et al., 2009]
RW Lam, SH Kennedy, S Grigoriadis, et al.
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.
J Affect Disord, 117 (2009), pp. S26-S43
[Lamberg et al., 2010]
T Lamberg, P Virtanen, J Vahtera, et al.
Unemployment, depressiveness and disability retirement: a follow-up study of the Finnish HeSSup population sample.
Soc Psychiatry Psychiatr Epidemiol, 45 (2010), pp. 259-264
[Landi et al., 2002]
F Landi, M Cesari, A Russo, et al.
Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community.
Clin Pharmacol Ther, 72 (2002), pp. 729-734
[Larun et al., 2006]
L Larun, LV Nordheim, E Ekeland, et al.
Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst.
Rev, (2006),
[Lavretsky et al., 2011]
H Lavretsky, LL Alstein, RE Olmstead, et al.
Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial.
Am J Geriatr Psychiatry, 19 (2011), pp. 839-850
[Lee et al., 2010]
MS Lee, HY Lee, SG Kang, et al.
Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders.
J Affect Disord, 123 (2010), pp. 216-221
[Leo and Ligot, 2007]
RJ Leo, JS Ligot Jr.
A systematic review of randomized controlled trials of acupuncture in the treatment of depression.
J Affect Disord, 97 (2007), pp. 13-22
[Lerner et al., 2010]
D Lerner, DA Adler, WH Rogers, et al.
Work performance of employees with depression: the impact of work stressors.
J Health Promot, 24 (2010), pp. 205-213
[Liebowitz and Tourian, 2010]
MR Liebowitz, KA Tourian.
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials.
Prim Care Companion J Clin Psychiatry, 12 (2010),
[Lin et al., 2011]
HS Lin, SR Erickson, R Balkrishnan.
Antidepressant Utilization, Adherence, and Health Care Spending in the United States: The Case of MDD Patients 2000-2007.
Health Outcomes Res Med, 2 (2011), pp. e79-e89
[Linde et al., 2008]
K Linde, MM Berner, L Kriston.
St John's wort for major depression.
Cochrane Database Syst Rev, (2008),
[Lobo et al., 2002]
A Lobo, L Chamorro, A Luque, et al.
Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales.
Med Clin (Barc), 118 (2002), pp. 493-499
[Londborg et al., 2000]
PD Londborg, WT Smith, V Glaudin, et al.
Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression.
J Affect Disord, 61 (2000), pp. 73-79
[Löwe et al., 2004]
B Löwe, K Kroenke, W Herzog, et al.
Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9).
J Affect Disord, 81 (2004), pp. 61-66
[Ma and Teasdale, 2004]
SH Ma, JD Teasdale.
Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects.
J Consult Clin Psychol, 72 (2004), pp. 31-40
[Maina et al., 2009]
G Maina, G Rosso, F Bogetto.
Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long-term results.
J Affect Disord, 114 (2009), pp. 200-207
[Malhi et al., 2009]
GS Malhi, D Adams, R Porter, et al.
Clinical Overview: Clinical practice recommendations for depression.
Acta Psychiatr Scand, (2009), pp. 8-26
[Malt et al., 1999]
UF Malt, OH Robak, HP Madsbu, et al.
The Norwegian naturalistic treatment study of depression in general practice (NORDEP). I: Randomised double-blind study.
BMJ, 318 (1999), pp. 1180-1184
[Manber et al., 2008]
R Manber, JD Edinger, JL Gress, et al.
Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia.
Sleep, 31 (2008), pp. 489-495
[Markowitz, 2008]
JC Markowitz.
When should psychotherapy be the treatment of choice for major depressive disorder?.
Curr Psychiatry Rep, 10 (2008), pp. 452-457
[Martinez et al., 2010]
C Martinez, TL Assimes, D Mines, et al.
Use of venlafaxine compared with other antidepressives and the risk of sudden cardiac death or near death: a nested case-control study.
BMJ, 340 (2010), pp. c249
[Martín-Merino et al., 2010]
E Martín-Merino, A Ruigómez, L García, et al.
Depression and treatment with antidepresivos are associated with the development of gastro-oesophageal reflux disease.
Aliment Pharmacol Ther, 31 (2010), pp. 1132-1140
[Mather et al., 2002]
AS Mather, C Rodríguez, MF Guthrie, et al.
Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: randomised controlled trial.
Br J Psychiatry, 180 (2002), pp. 411-415
[McDermott and Ebmeier, 2009]
L McDermott, KP Ebmeier.
A meta-analysis of depression severity and cognitive function.
J Affect Disord, 119 (2009), pp. 1-8
[McGrath et al., 2008]
PJ McGrath, AY Khan, MH Trivedi, et al.
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
J Clin Psychiatry, 69 (2008), pp. 1847-1855
[McGrath et al., 2006]
PJ McGrath, JW Stewart, FM Quitkin, et al.
Predictors of relapse in a prospective study of fluoxetine treatment of major depression.
Am J Psychiatry, 163 (2006), pp. 1542-1548
[Mead et al., 2008]
GE Mead, W Morley, P Campbell, et al.
Exercise for depression.
Cochrane Database Syst Rev, (2008),
[Meyboom et al., 2000]
RH Meyboom, M Lindquist, AK Flygare, et al.
The value of reporting therapeutic ineffectiveness as an adverse drug reaction.
Drug Saf, 23 (2000), pp. 95-99
[Möller, 2006]
HJ Möller.
Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review.
Eur Arch Psychiatry Clin Neurosci, 256 (2006), pp. 476-496
[Molyneux et al., 2008]
G Molyneux, G McCarthy, S McEniff, et al.
Prevalence and predictors of carer burden and depression in carers of patients referred to an old age psychiatric service.
Int Psychogeriatrics, 20 (2008), pp. 1193-1202
[Mota-Pereira et al., 2011]
J Mota-Pereira, J Silverio, S Carvalho, et al.
Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder.
J Psychiatr Res, 45 (2011), pp. 1005-1011
[Mottram et al., 2000]
P Mottram, K Wilson, J Copeland.
Validation of the Hamilton Depression rating scale and montgommery and asberg rating scales in terms of AGECAT depression cases.
Int J Geriatr Psychiatry, 15 (2000), pp. 1113-1119
[Mottram et al., 2006]
PG Mottram, K Wilson, JJ Strobl.
Antidepresivos for depressed elderly.
Cochrane Database Syst Rev, (2006),
[Mueller et al., 1999]
TI Mueller, AC Leon, MB Keller, et al.
Recurrence after recovery from major depressive disorder during 15 years of observational follow-up.
Am J Psychiatry, 156 (1999), pp. 1000-1006
[Mukaino et al., 2005]
Y Mukaino, J Park, A White, et al.
The effectiveness of acupuncturefor depression – a systematic review of randomised controlled trials.
Acupunct Med, 23 (2005), pp. 70-76
[Mulder et al., 2009]
RT Mulder, CM Frampton, SE Luty, et al.
Eighteen months of drug treatment for depression: predicting relapse and recovery.
J Affect Disord, 114 (2009), pp. 263-270
[Mulder et al., 2006]
RT Mulder, PR Joyce, CMA Frampton, et al.
Six months of treatment for depression: outcome and predictors of the course of illness.
Am J Psychiatry, 163 (2006), pp. 95-100
[Müller et al., 2003]
MJ Müller, H Himmerich, B Kienzle, et al.
Differentiating moderate and severe depression using the Montgomery–Åsberg depression rating scale (MADRS).
J Affect Disord, 77 (2003), pp. 255-260
[Nahrstedt and Butterweck, 1997]
A Nahrstedt, V Butterweck.
Biologically active and other chemical constitutents of the herb hypericum perforatum L.
Pharmacopsychiatry, 30 (1997), pp. 129-134
[National Collaborating Centre for Mental Health, 2010]
National Collaborating Centre for Mental Health.
Depression. The NICE Guideline on the treatment and management of depression in adults (Updated Edition) (National Clinical Practice Guideline 90). National Institute for Health and Clinical Excellence (NICE), The British Psychological Society and The Royal College of Psychiatrists, (2010),
[Nelson et al., 2009]
JC Nelson, K Delucchi, LS Schneider.
Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis.
Int J Geriatr Psychiatry, 24 (2009), pp. 539-544
[Nierenberg et al., 2000]
AA Nierenberg, AH Farabaugh, JE Alpert, et al.
Timing of onsent of antidepressant response with fluoxetine treatment.
Am J Psychiatry, 157 (2000), pp. 1423-1428
[Nierenberg et al., 1995]
AA Nierenberg, NE McLean, JE Alpert, et al.
Early nonresponse to fluoxetine as a predictor of poor 8-week outcome.
Am J Psychiatry, 152 (1995), pp. 1500-1503
[Nierenberg et al., 2004]
AA Nierenberg, FM Quitkin, C Kremer, et al.
Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse.
Neuropsychopharmacology, 29 (2004), pp. 1012-1018
[NIMH/NIH Consensus Development Conference Statement, 1985]
NIMH/NIH Consensus Development Conference Statement.
Mood disorders: pharmacologic prevention of recurrences.
Am J Psychiatry, 142 (1985), pp. 469-476
[Oestergaard and Møldrup, 2011]
S Oestergaard, C Møldrup.
Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis.
J Affect Disord, 131 (2011), pp. 24-36
[Olfson et al., 2006]
M Olfson, SC Marcus, M Tedeschi, et al.
Continuity of antidepressant treatment to adults with depression in the United States.
Am J Psychiatry, 163 (2006), pp. 101-108
[Opatrny et al., 2008]
L Opatrny, JA Delaney, S Suissa.
Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look.
Br J Clin Pharmacol, 66 (2008), pp. 76-81
[Pampallona et al., 2004]
S Pampallona, P Bollini, G Tibaldi, et al.
Combined pharmacotherapy and psychological treatment for depression: a systematic review.
Arch Gen Psychiatry, 61 (2004), pp. 714-719
[Papakostas et al., 2006]
GI Papakostas, RH Perlis, MJ Scalia, et al.
A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.
J Clin Psychopharmacol, 26 (2006), pp. 56-60
[Parikh et al., 2009]
S Parikh, Z Segal, S Grigoriadis, et al.
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication.
J Affect Disord, 117 (2009), pp. S15-S25
[Patten et al., 2009]
S Patten, J Wang, J Williams, et al.
Prospective evaluation of the effect of major depression on working status in a population sample.
Can J Psychiatry, 54 (2009), pp. 841-845
[Patten et al., 2009]
SB Patten, SH Kennedy, RW Lam, et al.
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management.
J Affect Disord, 117 (2009), pp. S5-S14
[Patten and Lee, 2004]
SB Patten, RC Lee.
Refining estimates of major depression incidence and episode duration in Canada using a Monte Carlo Markov model.
Med Decis Making, 24 (2004), pp. 351-358
[Paykel et al., 2005]
ES Paykel, J Scott, PL Cornwall, et al.
Duration of relapse prevention after cognitive therapy in residual depression: follow-up of controlled trial.
Psychol Med, 35 (2005), pp. 59-68
[Perlis et al., 2002]
RH Perlis, AA Nierenberg, JE Alpert, et al.
Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
J Clin Psychopharmacol, 22 (2002), pp. 474-480
[Piek et al., 2010]
E Piek, K van der Meer, WA Nolen.
Guideline recommendations for long-term treatment of depression with antidepressants in primary care–a critical review.
Eur J Gen Pract, 16 (2010), pp. 106-112
[Piet and Hougaard, 2011]
J Piet, E Hougaard.
The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: A systematic review and meta-analysis.
Clin Psychol Rev, 31 (2011), pp. 1032-1040
[Pinchasov et al., 2000]
BB Pinchasov, AM Shurgaja, OV Grischin, et al.
Mood and energy regulation in seasonal and non-seasonal depression before and after midday treatment with physical exercise or bright light.
Psychiatry Res, 94 (2000), pp. 24-92
[Pinto-Meza et al., 2008]
A Pinto-Meza, A Fernández, A Serrano-Blanco, et al.
Adequacy of antidepressant treatment in spanish primary care: a naturalistic six-month follow-up study.
Psychiatr Serv, 59 (2008), pp. 78-83
[Pintor et al., 2003]
L Pintor, C Gastó, V Navarro, et al.
Relapse of major depression after complete and partial remission during a 2-year follow-up.
J Affect Disord, 73 (2003), pp. 237-244
[Pintor et al., 2004]
L Pintor, X Torres, V Navarro, et al.
Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up?.
J Affect Disord, 82 (2004), pp. 291-296
[Posada-Villa et al., 2004]
J Posada-Villa, S Aguilar-Gaxiola, C Magaña, et al.
Prevalencia de trastornos mentales y uso de servicios: Resultados preliminares del Estudio Nacional de salud mental Colombia 2003.
Rev Col Psiquiatría, 3 (2004), pp. 241-262
[Posternak and Zimmerman, 2005]
MA Posternak, M Zimmerman.
Is there a delay in the antidepressant effect?.
J Clin Psychiatry, 66 (2005), pp. 148-158
[Priebe and Briiker, 1997]
S Priebe, M Briiker.
Initial response to active drug and placebo predicts outcome of antidepressant treatment.
Eur Psychiatry, 12 (1997), pp. 28-33
[Quah-Smith et al., 2005]
JI Quah-Smith, WM Tang, J Russell.
Laser acupuncture for mild to moderate depression in a primary care setting-a randomised controlled trial.
Acupunct Med, 23 (2005), pp. 103-111
[Quera-Salva et al., 2011]
MA Quera-Salva, G Hajak, P Philip, et al.
Comparación of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
Int Clin Psychopharmacol, 26 (2011), pp. 252-262
[Quitkin et al., 2003]
FM Quitkin, E Petkova, PJ McGrath, et al.
When should a trial of fluoxetine for major depression be declared failed?.
Am J Psychiatry, 160 (2003), pp. 734-740
[Quitkin et al., 1984]
FM Quitkin, JG Rabkin, D Ross, et al.
Identification of true drug response to antidepressants. Use of pattern analysis.
Arch Gen Psychiatry, 41 (1984), pp. 782-786
[Ramana et al., 1995]
R Ramana, ES Paykel, Z Cooper, et al.
Remission and relapse in major depression: a two-year prospective follow-up study.
Psychol Med, 25 (1995), pp. 1161-1170
[Raue et al., 2009]
PJ Raue, HC Schulberg, M Heo, et al.
Patients depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study.
Psychiatr Serv, 60 (2009), pp. 337-343
[Reesal et al., 2001]
RT Reesal, RW Lam, CANMAT Depression Work Group.
Clinical guidelines for the treatment of depressive disorders. II. Principles of Management.
Can J Psychiatry, 46 (2001), pp. S21-S28
[Reimherr et al., 1998]
FW Reimherr, JD Amsterdam, FM Quitkin, et al.
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.
Am J Psychiatry, 155 (1998), pp. 1247-1253
[Reynolds et al., 1999]
CF Reynolds 3rd, E Frank, MA Dew, et al.
Treatment of 70(+)-year-olds with recurrent major depression. Excellent short-term but brittle long-term response.
Am J Geriatr Psychiatry, 7 (1999), pp. 64-69
[Reynolds et al., 1988]
CF Reynolds 3rd, CC Hoch, DJ Kupfer, et al.
Bedside differentiation of depressive pseudodementia from dementia.
Am J Psychiatry, 145 (1988), pp. 1099-1103
[Rush et al., 2006]
AJ Rush, MH Trivedi, SR Wisniewski, et al.
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
Am J Psychiatry, 163 (2006), pp. 1905-1917
[Russell and Kazantzis, 2008]
J Russell, N Kazantzis.
Medication beliefs and adherence to antidepressants in primary care.
N Z Med J, 121 (2008), pp. 14-20
[Sánchez Díaz, 2005]
N Sánchez Díaz.
La carga de la enfermedad.
Rev Col Psiquiatría, 34 (2005), pp. 298-304
[Sarmiento et al., 2010]
M Sarmiento, S Strejilevich, C Gómez-Restrepo, et al.
Uso de medicinas complementarias y alternativas en pacientes con trastorno afectivo bipolar en Colombia.
Rev Col Psiquiatría, 39 (2010), pp. 665-682
[Schneeweiss et al., 2010]
S Schneeweiss, AR Patrick, DH Solomon, et al.
Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Arch Gen Psychiatry, 67 (2010), pp. 497-506
[Scottish Intercollegiate Guidelines Network (SIGN), 2010]
Scottish Intercollegiate Guidelines Network (SIGN).
Non-pharmaceutical management of depression in adults A national clinical guideline Scottish Intercollegiate Guidelines Network 114, SIGN, (2010),
[Serna et al., 2010]
MC Serna, I Cruz, J Real, et al.
Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database.
Eur Psychiatry, 25 (2010), pp. 206-213
[Shimazu et al., 2011]
K Shimazu, S Shimodera, Y Mino, et al.
Family psychoeducation for major depression: randomised control trial.
Br J Psych, 198 (2011), pp. 385-390
[Simon et al., 2011]
GE Simon, JD Ralston, J Savarino, et al.
Randomized trial of depression follow-up care by online messaging.
J Gen Intern Med, 26 (2011), pp. 698-704
[Simon, 2000]
JE Simon.
Long-term prognosis of depression in primary care.
Bull World Health Organ, 78 (2000), pp. 439-445
[Simpson et al., 2003]
S Simpson, R Corney, P Fitzgerald, et al.
A randomized controlled trial to evaluate the effectiveness and cost-effectiveness of psychodynamic counselling for general practice patients with chronic depression.
Psychol Med, 33 (2003), pp. 229-239
[Singh et al., 2011]
SP Singh, V Singh, N Kar.
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
Int J Neuropsychopharmacol, (2011), pp. 1-12
[Sirey et al., 2010]
JA Sirey, ML Bruce, HC Kales.
Improving antidepressant adherence and depression outcomes in primary care: the treatment initiation and participation program.
Am J Geriatr Psychiatry, 18 (2010), pp. 554-562
[Smith et al., 2010]
C Smith, PPJ Hay, H MacPherson.
Acupunture for depression.
Cochrane Database Syst Rev, (2010),
[Song et al., 2007]
Y Song, D Zhou, J Fan, et al.
Effects of electroacupuncture and fluoxetine on the density of GTP-binding-proteins in platelet membrane in patients with major depressive disorder.
J Affect Disord, 98 (2007), pp. 253-257
[Spijker et al., 2002]
J Spijker, R de Graaf, RV Bijl, et al.
Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS).
Br J Psychiatry, 181 (2002), pp. 208-213
[Stahl et al., 2010]
SM Stahl, M Fava, MH Trivedi, et al.
Agomelatine in the treatment of major depressive disorder: an 8 week, multicenter, randomized placebo trial.
J Clin Psychiatry, 71 (2010), pp. 616-626
[Stassen et al., 1993]
HH Stassen, A Delini-Stula, J Angst.
Time course of improvement under antidepressant treatment: a survival-analytical approach.
Eur Neuropsychopharmacol, 3 (1993), pp. 127-135
[Steffens et al., 2003]
D Steffens, D McQuoid, KR Rama Krishnan.
Parcial response as a predictor of outcome in geriatric depression.
Am J Geriatr Psychiatry, 11 (2003), pp. 340-348
[Stone et al., 2009]
M Stone, T Laugghren, ML Jones, et al.
Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.
BMJ, 339 (2009), pp. b2880
[Strunk et al., 2010]
DR Strunk, MA Brotman, RJ DeRubeis.
The process of change in cognitive therapy for depression: predictors of early inter-session symptom gains.
Behav Res Ther, 48 (2010), pp. 599-606
[Stukenberg et al., 1990]
K Stukenberg, J Dura, J Kiecolt-Glaser.
Depression screening scale validation in an elderly, community-dwelling population.
J Consult Clin Psychol, 2 (1990), pp. 134-138
[Szegedi et al., 2009]
A Szegedi, WT Jansen, A van Willigenburg, et al.
Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.
J Clin Psychiatry, 70 (2009), pp. 344-353
[Szegedi et al., 2003]
A Szegedi, MJ Müller, I Anghelescu, et al.
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
J Clin Psychiatry, 64 (2003), pp. 413-420
[Taylor, 2010]
CB Taylor.
Measurement.
How to practice evidence-based psychiatry,
[Taylor et al., 2006]
MJ Taylor, N Freemantle, JR Geddes, et al.
Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.
Arch Gen Psychiatry, 63 (2006), pp. 1217-1223
[Teasdale et al., 2000]
JD Teasdale, JMG Williams, JM Soulsby, et al.
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.
J Consult Clin Psychol, 68 (2000), pp. 615-623
[The World Mental Health Survey Consortium, 2004]
The World Mental Health Survey Consortium.
Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys.
JAMA, 291 (2004), pp. 2581-2590
[Trifirò et al., 2010]
G Trifirò, J Dieleman, EF Sen, et al.
Risk of ischemic stroke associated with antidepressant drug use in elderly persons.
J Clin Psychopharmacol, 30 (2010), pp. 252-258
[Trivedi et al., 2006]
MH Trivedi, TL Greer, BD Grannemann, et al.
Exercise as an augmentation strategy for treatment of major depression.
J Psychiatr Pract, 12 (2006), pp. 205-213
[Trivedi et al., 2007]
MH Trivedi, EH Lin, WJ Katon.
Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.
CNS Spectr, 12 (2007), pp. 1-27
[Trivedi et al., 2006]
MH Trivedi, AJ Rush, SR Wisniewski, et al.
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Am J Psychiatry, 163 (2006), pp. 28-40
[Uher et al., 2000]
R Uher, A Farmer, N Henigsberg, et al.
A systematic review of newer pharmacotherapies for depression in adults: evidence report summary.
Ann Intern Med, 132 (2000), pp. 743-756
[Uher et al., 2009]
R Uher, O Mors, J Hauser, et al.
Body weight as a predictor of antidepressant efficacy in the GENDEP project.
J Affect Disord, 118 (2009), pp. 147-154
[Van Calker et al., 2009]
D Van Calker, I Zobel, P Dykierek, et al.
Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy.
J Affect Disord, 114 (2009), pp. 243-253
[Van der Werff et al., 2010]
E Van der Werff, CE Verboom, B Penninx, et al.
Explaining heterogeneity in disability associated with current major depressive disorder: Effects of illness characteristics and comorbid mental disorders.
J Affect Disord, 127 (2010), pp. 203-210
[Van Londen et al., 1998]
L Van Londen, RP Molenaar, JG Goekoop, et al.
Three- to 5-year prospective follow-up of outcome in major depression.
Psychol Med, 28 (1998), pp. 731-735
[Vergouwn et al., 2003]
AC Vergouwn, A Bakker, WJ Katon, et al.
Improving adherence to antidepressants: a systematic review of interventions.
J Clin Psychiatry, 64 (2003), pp. 1415-1420
[Viguera et al., 1998]
AC Viguera, RJ Baldessarini, J Friedberg.
Discontinuing antidepressant treatment in major depression.
Harv Rev Psychiatry, 5 (1998), pp. 293-306
[Vittengl et al., 2007]
JR Vittengl, LA Clark, TW Dunn, et al.
Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects.
J Consult Clin Psychol, 75 (2007), pp. 475-488
[Wang et al., 2008]
H Wang, H Qi, BS Wang, et al.
Is acupuncture beneficial in depression: a meta-analysis of 8 randomized controlled trials?.
J Affect Disord, 111 (2008), pp. 125-134
[Wang et al., 2011]
J Wang, X Liu, C Daniel Mullins.
Treatment adherence and persistence with duloxetine, venalafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Curr Med Res Opin, 27 (2011), pp. 1303-1313
[Watanabe et al., 2011]
N Watanabe, IM Omori, A Nakagawa, et al.
Mirtazapina versus other antidepressive agents for depression.
Cochrane Database Syst Rev, (2011),
[Watanabe et al., 2010]
N Watanabe, IM Omori, A Nakagawa, et al.
Safety reporting and adverse-event profile of mirtazapina described in randomized controlled trials in comparison with other classes of antidepressives in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
CNS Drugs, 24 (2010), pp. 35-53
[Whyte et al., 2004]
EM Whyte, MA Dew, A Gildengers, et al.
Time course of response to antidepressants in late-life major depression. Therapeutic implications.
Drugs Aging, 21 (2004), pp. 531-554
[Williams, 2001]
BW Williams.
Standardizing the Hamilton Depression Rating Scale: past, present, and future.
Eur Arch Psychiatry Clin Neurosci, 251 (2001), pp. 6-12
[Williams et al., 2007]
JW Williams Jr, M Gerrity, T Holsinger, et al.
Systematic review of multifaceted interventions to improve depression care.
Gen Hosp Psychiatry, 29 (2007), pp. 91-116
[Wilson et al., 2008]
KC Wilson, PG Mottram, CA Vassilas.
Psychotherapeutic treatments for older depressed people.
Cochrane Database Syst Rev, (2008),
[Woo et al., 2011]
JM Woo, W Kim, TY Hwang, et al.
Impact of depression on work productivity and its improvement after outpatient treatment with antidepressants.
Value Health, 14 (2011), pp. 475-482
[Woolcott, 2009]
JC Woolcott.
Meta-analysis of the Impact of 9 medication classes on falls in elderly persons.
Arch Intern Med, 169 (2009), pp. 1952-1960
[Woolley et al., 2010]
SB Woolley, L Fredman, JW Goethe, et al.
Hospital patients' perceptions during treatment and early discontinuation of serotonin selective reuptake inhibitor antidepressants.
J Clin Psychopharmacol, 30 (2010), pp. 716-719
[Wu et al., 2012]
Q Wu, AF Bencaz, JG Hentz, et al.
Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies.
Osteoporos Int, 23 (2012), pp. 365-375
[Zhang et al., 2009]
WJ Zhang, XB Yang, BL Zhong.
Combination of acupuncture and fluoxetine for depression: a randomized, double-blind, sham-controlled trial.
J Altern Complement Med, 15 (2009), pp. 837-844
[Zimmerman et al., 2004]
M Zimmerman, M Posternak, M Friedman, et al.
Which factors influence psychiatrists' selection of antidepressants?.
Am J Psychiatry, 161 (2004), pp. 1285-1289
[Zivin et al., 2009]
K Zivin, D Ganoczy, PN Pfeiffer, et al.
Antidepressant adherence after psychiatric hospitalization among v a patients with depression.
Adm Policy Ment Health, 36 (2009), pp. 406-415
La Guía de Atención Integral completa fue desarrollada por el Grupo que aparece en el anexo de este artículo. Este artículo-resumen fue redactado por los integrantes del grupo que se mencionan bajo el título. Financiación: El desarrollo de la Guía de Atención Integral fue financiado por el Ministerio de Salud y Protección Social y por el Departamento Administrativo de Ciencia, Tecnología e Innovación (Colciencias), mediante Contrato 126 de 2010 suscrito con la Pontificia Universidad Javeriana. Convocatoria 500 de 2009 de Colciencias (Conformación de un banco de proyectos para el desarrollo de Guías de Atención Integral (GAI) Basadas en Evidencia), fue elegido por el Consejo del Programa Nacional de Ciencia y Tecnología de la Salud, el proyecto fue liderado por la Pontificia Universidad Javeriana, en alianza con la Universidad de Antioquia y la Universidad Nacional de Colombia (Alianza CINETS).
Conflictos de interés: Los autores manifiestan que no tienen conflictos de interés en este artículo.
Copyright © 2012. Asociación Colombiana de Psiquiatría
Publique en
Revista Colombiana de Psiquiatría
Herramientas
Artículos
recomendados
recomendados
Rev Colomb Psiquiatr. 2024;53:448-57
Rev Colomb Psiquiatr. 2025;54:398-404
10.1016/j.rcp.2024.03.006
Revista Colombiana de Psiquiatría se adhiere a los principios y procedimientos dictados por el Committee on Publication Ethics (COPE)
www.publicationethics.org.
www.publicationethics.org.
Open access
Esta obra está licenciada por una Licencia Creative Commons Attribution 4.0 International License.
